Psychological Impact on Parents of an Inconclusive Diagnosis Following Newborn Bloodspot Screening for Cystic Fibrosis: A Qualitative Study. by Johnson, Faye et al.
International Journal of
Neonatal Screening
Article
Psychological Impact on Parents of an Inconclusive
Diagnosis Following Newborn Bloodspot Screening
for Cystic Fibrosis: A Qualitative Study
Faye Johnson 1, Kevin W. Southern 2 and Fiona Ulph 1,*
1 Division of Psychology & Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health,
University of Manchester, Manchester Academic Health Science Centre, Oxford Road, Manchester M13 9PL,
UK; faye.johnson@manchester.ac.uk
2 Institute of Translational Medicine, University of Liverpool, Liverpool L12 2AP, UK;
K.W.Southern@liverpool.ac.uk
* Correspondence: Fiona.ulph@manchester.ac.uk
Received: 26 March 2019; Accepted: 28 May 2019; Published: 11 June 2019


Abstract: Genetic results of uncertain clinical significance are being returned to parents following
newborn screening, representing a paradigm change in how society considers health and illness.
‘Cystic Fibrosis screen positive, inconclusive diagnosis’ (CFSPID) is a designation given to newborns
with a positive screening result for, but not a definitive diagnosis of, cystic fibrosis. We explored
the psychological impact of receiving a CFSPID result on parents. Five semi-structured interviews
were conducted with eight parents whose children have CFSPID. Interpretative phenomenological
analysis identified these themes: “The way we were told”: ‘diagnosis as a traumatic event’ focused on
how parents were distressed and dissatisfied by the initial screening result communication, ‘Facing
and challenging traditional ideas about health and illness’ explored the emerging problem of how
CFSPID does not fit the commonly accepted medical model, and ‘Making certainty out of uncertainty’
explored the varying strategies parents developed to adapt to the uncertainty regarding their child’s
prognosis. Findings suggest that CFSPID results caused parents’ distress, initiated with the first
communication of the result and persisting thereafter. Our data suggests approaches to the delivery
of CFSPID results that may reduce the impact. Work is needed to close the gap between healthcare
advances and societies commonly held medical model.
Keywords: newborn screening; qualitative; communication; CFSPID; uncertainty; impact;
psychological; parent
1. Introduction
Newborn bloodspot screening (NBS) allows for early identification and management of genetic
conditions [1]. NBS can now identify abnormalities of uncertain clinical significance [2]. ‘Cystic fibrosis
screen positive, inconclusive diagnosis’ (CFSPID) is a designation given to infants with a positive NBS
result, but not a definitive diagnosis of cystic fibrosis (CF). Evidence suggests the number who go
on to develop some form of CF varies based on the NBS protocol, but at present, no clear indication
can be given to parents about the likelihood that their child will develop CF, the type of CF, or when
they might show symptoms [3]. Both the ECFS Neonatal Screening Working Group and the CFF have
produced guidance on clinical management which stress the importance of clear communication [4,5].
However, the guidance does not go any further or provide clear guidance on what the content of that
communication should be or how to ensure it is clear. This is important as research with parents who
received NBS carrier or false positive results suggests medically ‘benign’ results may have a significant
psychological impact [6,7], which is often moderated by communication efficacy.
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Furthermore, although it is acknowledged in the field that CFSPID designation may cause
uncertainty, a state which is known to cause distress, relatively little research has explored the
psychological impact of CFSPID for parents [8,9]. A questionnaire study suggested that parental
distress over CFSPID may be of a similar level to parents of children with definitive CF diagnoses [10].
However, questionnaires may not capture psychological complexity due to closed questions. Massie
and Gillam [11] considered various management options in CFSPID. Potential harms include
over-medicalisation and altered parental attachment. Nevertheless, their arguments are hypothetical.
One qualitative study has confirmed these potential harms are experienced by parents in a setting
where screening is mandatory and there may be health insurance implications [12], The purpose of
this paper was to conduct further, in-depth research to underpin communication guidance. This paper
aimed to address the gap in communication guidance via an in-depth exploration of the psychological
impact of a CFSPID designation on parents.
2. Materials and Methods
2.1. Study Design
A qualitative study using interpretative phenomenological analysis (IPA), which is an in-depth
method which is well suited to health psychology [13] and suitable for novel research topics and
small samples [14]. IPA was chosen as it enables the in-depth study of lived experience of small
homogenous groups [14] and acknowledges that the analysis involves the researchers’ interpretation
of the participants’ interpretations of their experiences. This is useful when the participants themselves
may not use psychological terminology or theories to interpret their experience, but one wants to
create an overall understanding of psychological factors in an experience. Inclusion criteria were
that parents had received a CFSPID result following NBS via the clinic. Parents who did not speak
fluent English were excluded due to funding constraints. Parents were excluded if their child had
died. Ethical approval was obtained from the NHS Health Research Authority (North West—Preston
Research Ethics Committee on 20 February 2018, No. 219764).
2.2. Recruitment and Consent
Convenience sampling was used whereby parents who had received a CFSPID designation for
their child were recruited via a CF clinic in North West England. IPA is typically conducted with small
sample sizes, congruent with its emphasis on individual meaning [15]. The decision to cease recruiting
was based on IPA guidelines to provide sufficient time within the project to enable in-depth analysis of
the data and suitable sample sizes for projects, an ongoing review of the issues covered in interviews
to establish data sufficiency, and the rate of return of forms from potential participants.
Study packs were distributed to parents by clinic staff. Parents returned a “consent to contact”
form if they were interested in hearing more about participation. They were then called by F.J. to
discuss the interview and set an interview time if wanted. Before the interview started, salient aspects
of the participant information sheet were discussed, and participants could ask questions. If they
agreed to proceed, they were asked to sign a consent form.
2.3. Participants
Three couples and two mothers participated. The parents could choose whether to be interviewed
together and all couples requested this. All participants were interviewed once. Parent characteristics
can be seen in Table 1. Children were age 2–8 years, with no siblings with CFSPID.
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Table 1. Characteristics of parents.
n = 8 (families interviewed = 5)
Ethnicity
White British 8
Gender
Female 5
Male 3
Family unit
Lives with child’s father 7
Separated from child’s father 1
Parents taking part in interview
Mother and father together 6
Mother only 2
Highest educational attainment
Degree or higher 7
GCSE (school to 16 years) 1
Number of Children
2 7
3 1
2.4. Interviews
The semi-structured interview schedule was developed with CF and qualitative NBS research
experts, guided by literature (available online). Topics included: initial result communication,
impact of CFSPID on identity and parental role, telling others/the child about CFSPID, role of
healthcare professionals (HCPs), impact of CFSPID knowledge, and suggestions. Questions were open,
with flexible prompts to elicit more detail. Drawing tasks were used to help parents consider abstract
concepts. These included a series of concentric circles to enable parents to convey how close various
people who were involved in this time were to them and reflect on conversations. It also involved
stick diagrams of people depicting continuums from healthy and unhealthy to enable them to reflect
at different time points how they viewed their child (see interview schedule). The verbal responses
were analysed, rather than the drawings. Parents were interviewed at home by F.J., with interviews
lasting 50–150 min. Audio recordings of interviews were transcribed verbatim, removing identifiers.
Pseudonyms were used.
2.5. Ethical Approval
Data were analysed using Interpretative Phenomenological Analysis (IPA) [16]. Each transcript
was analysed separately before identifying patterns across the dataset. Analysis was supervised by
an experienced IPA researcher. Coding was checked for completeness and representation of the dataset
as a whole. Data exemplars were selected from each participant to illustrate how each concept applies
to each participant (case within theme), in line with IPA guidance for a sample this size [16]. Due to
the researcher’s own background and the focus of much of their training in psychology and health
services, it is possible that CFSPID was approached as a problem to be solved, i.e., expecting that
parents would have issues with their child’s CFSPID designation, where perhaps they may not have
done. These preconceptions may have influenced participants’ responses, for instance through small
cues during the interview process. The researcher’s interpretative analysis of the interviews may to
some degree have been conducted through this ‘problem solving’ lens.
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3. Results
3.1. “The Way We were Told”: Diagnosis as a Traumatic Event
3.1.1. Intrusion and Taking Away of Control
All parents described similar experiences of unexpected visitors to their homes, interrupting
everyday life with a newborn. Sue, whose husband was working away, described this:
SUE: “A lady come to the door, and she just said [ . . . ] she’d come in to talk to us, I’d no idea who she was
or anything like that, so she just came in, and then she sat me down.”
The behaviour of the professional felt intrusive and transgressive—unlike usual interactions,
the visitor came in without asking and without Sue knowing her identity. Sue appears not to have had
control in this moment, which immediately raised alarm—Sue’s husband “had to rush home.”
Guy, whose wife Liz was out at the time, described the visitors as “[ . . . ] insistent, y’know, get your
wife back home”. Guy instantly felt something was wrong:
GUY: “Got a knock on the door, two health visitors come round, unannounced, and I know from experience
when people come around unannounced it’s not great news.”
Molly, who was at home with her two young daughters, described her experience:
MOLLY: “The door went, in walked two health visitors to basically tell, tell us the news [ . . . ] and especially
because I was like breastfeeding as they arrived as well, you just, you feel very vulnerable [ . . . ] it’s just not
a nice thing to have strangers turn up at your house.”
Again, they came uninvited, immediately creating a power imbalance. Molly explained that she
felt vulnerable—arguably the antithesis of what healthcare should feel like.
Sadie also experienced the timing of the visit to be inappropriate and intrusive:
SADIE: “kids’ dad was saying ‘Well can’t you come back?’ and she was going ‘No, I need to come in
now’ . . . cos I was having a sleep with Mia, she went ‘You need to wake mum up’, so we got told to come down
the stairs.”
Although medically necessary, the visitor’s insistence on coming in takes control away from Sadie
and her partner and connotes a sense of worrying urgency.
For another parent, the sense of alarm, vulnerability, and loss of control was harmful:
ANNA: “They said ‘Can you talk? We need to speak to you. Can somebody have the baby?’ [ . . . ] and I
said, ‘Yeah, why?’ and she said ‘Just, you need to get, give your baby give the baby to your mum.’ [ . . . ] and she
just sat us down didn’t she and said ‘I’ve got some [pause] bad news’, [ . . . ] I honestly thought she was coming
to have me sectioned.”
The urgency of the visit, intensified by having to hand the baby over, compounded Anna’s feelings
of vulnerability. Having experienced postnatal depression, Anna was frightened that she was being
sectioned—an ultimate example of having control taken away. The visits, and the manner in which
they were conducted—the sense of urgency, without prior warning—sent the message to parents that
something was terribly wrong and impacted on their interpretations of the screening result as a serious,
life-threatening diagnosis. In general, parents had strong, lasting memories of the visits as negatively
affecting their experience of home life with their new baby.
3.1.2. Fear, Grief, and Threat to Child’s Life
Parents varied in their willingness to discuss their psychological responses to diagnosis during
the interview, some appeared more pragmatic, suggesting “the way you find out” (Molly) should be
changed. Communication of the screening result led to all parents’ initial belief that their child had
an unequivocal CF diagnosis. Liz described the fear this caused:
LIZ: “I think it’s scary wasn’t it? Cos all of a sudden, because the way it was put across to us by the health
visitors is that Ava had CF and that was final [ . . . ] wasn’t a chance that she didn’t have CF so it was us trying
to accept that [ . . . ] it was scary, upsetting, worrying—of how we were gonna manage—A child with CF.”
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Liz, a healthcare professional with knowledge of CF, was forced to face a challenging new future.
All parents knew of CF as serious, with a poor prognosis, as discussed by Sadie:
SADIE: “The time’s gonna come when Mia’s in hospital, she’s gonna miss out on school trips gonna miss
out on birthdays [ . . . ] might not even have a Christmas, we don’t know.”
Though she knows that Mia (now 8) is well, Sadie maintains that she “is not a normal child”,
and appears to have retained the fear of her daughter’s life being severely limited: “Is the day and the
time gonna come where, y’know, it’s gonna kill us?”
Harry interpreted his son Ben’s diagnosis through his own personal history of loss:
“Bombshell wasn’t it? It was confusing, cos my dad died when I was 10, and I imagined Noah at that age
at his brother’s funeral, and that was all that was going through my head at the time.”
Harry emotively described his all-consuming grief, the term ‘bombshell’ connoting total
devastation, illustrating how diagnosis is not received in isolation, but interpreted in the context of
personal factors. The ultimate fear of a child dying was also experienced by Sue:
SUE: “She said it was cystic fibrosis [ . . . ] I just kept saying to her ‘Oh my god is she gonna die, is she
gonna die?’, and she just said ‘Well I don’t, I can’t say anything like that obviously’ so she just said ‘You need to
speak to someone at the hospital’.”
The visitor’s communication took Sue immediately to fearing and begging for her child’s life.
The visitor appeared to give a standardised pat response, leaving Sue’s desperate need unmet.
3.1.3. Information Sufficiency
Parents unanimously felt initial information was inadequate and inappropriate. Disappointment
and exasperation were palpable in their recounts:
JIM: “We didn’t get any kind of level of information really, apart from they said that this had come back
on the screening and they left a leaflet which was about CF [ . . . ] that said your child might not make it to 30.
And had no information other than that.”
They were visibly frustrated about the “very outdated” leaflet (Molly), blaming it for the initial
belief that Ruby had “classic CF [ . . . ] shortened life expectancy and all of that” (Jim). This is echoed by
Sue, whose visitor “was in and out within ten minutes”, as if on an errand:
“ . . . and she’d gone [sigh]. So she left us with a pamphlet, it was quite old it was an old pamphlet, it does it
needs a lot of updating, and when you go onto the internet and you read it up about it it’s very scary.”
Sue was triggered to fear for her daughter’s life, yet she did not feel she was given adequate
information. The phrases ‘she’d gone’ and ‘she left us’ suggest Sue felt abandoned. Although “you try
not to Google” (Liz), parents needed information as soon as the alarm was raised. Unfortunately, this led
to inappropriate information, perpetuating diagnosis fear:
HARRY: “I just couldn’t get my head round what it was, and I remember she said ‘Don’t go on the internet
to look at it’, what a ridiculous thing to say, who’s not gonna do that? So we went on the internet obviously,
and er after she’d gone, and that’s when you see things like iron lungs, average life expectancy 40, and you think
[expletive], pardon my French but . . . I dunno, it’s just, worst night ever wasn’t it.”
Harry suggests that parents’ strong need for information renders the suggestion of not going on
the internet unrealistic. Doing this after the visitor left sounds surreptitious, suggesting a breakdown
of trust between parents and healthcare professionals. Like Sue, the information exacerbated distress,
leaving a vivid impression five years later. Of note, many parents reported they were signposted to the
CF trust website by the hospital team and found this site was very useful, both in terms of information
and peer support from other families.
Sadie’s account differed from the other participants’, as at the time of the diagnosis she was in
an abusive relationship, and did not feel able to engage with the information being given:
“It wasn’t real [ . . . ] I was just numb and not understanding [ . . . ] I weren’t really that much aware of
what was really going on, all I was really trying to do was keep my head above water.”
Sadie’s account highlights the issue that, in difficult circumstances, there may be barriers to
understanding. Families may need additional support to understand the screening result.
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3.1.4. Extended Issues of Heightened Health Risk Perception
In the period following diagnosis, parents felt a range of negative emotions, such as Sue,
who questioned her parental role:
“What am I gonna do? Is she gonna be in and out of hospital all the time, is she gonna be really ill? How
am I gonna cope?” [ . . . ] It wasn’t so much emotional as trying to fit things in, and I think that’s the way I went
for a very long time.”
Sue was reacting to demands of managing a serious illness, causing anxiety and self-doubt, years
after she was told that Tilly had CFSPID (not CF). This eclipsed her ability to process her emotional
reaction. Molly and Jim had a visceral initial reaction to heightened health risk “ . . . cleaning constantly,
I had the most horrendous eczema on my hands, because I just wanted everywhere to be clean” (Molly) and were
perhaps the highest seekers of ongoing reassurance from professionals that they were doing “ . . . the
right thing” (Jim) for 4-year-old Ruby. The assumed burden of serious illness also affected other parents:
LIZ: “I felt really guilty for having her [ . . . ] It’s just a responsibility that you’ve had this child who’s now
got this horrible condition, and that we’ve made her.”
This burden of responsibility and self-blame is still remembered vividly two years later.
This extended ramification of genetic diagnosis was also felt by Anna and Harry:
ANNA: “I used to say were me and Harry not meant to have children, cos our faulty genes clashed together
[ . . . ] y’know, if you’d had children with someone else you wouldn’t have had a child with CF probably.”
The guilt and blame associated with the diagnosis caused Anna to doubt her relationship with
her husband. Again, 5-year-old Ben is referred to as having CF. Anna and Harry had wanted to have
another baby but, due to the diagnosis, did not go on to do so. Both have experienced mental ill health,
which they attributed to the impact of the diagnosis:
HARRY: “Everything changed for us didn’t it, everything blew up [ . . . ] Looking back we probably both
had depression didn’t we, at some stage over the last five years.”
Again, Harry’s language connotes the destructive effect the diagnosis had on him and his family.
In Sadie’s relationship with her ex-husband, the diagnosis added a further stressor:
“I honestly believe that I stayed with him because of Mia’s condition [ . . . ] it was ‘can I manage raising
a child with a chronic illness on my own?’”
Like Sue, Sadie doubted her ability to care for her child. In an abusive relationship, this was
exacerbated and the idea of Mia’s “chronic illness” further controlled Sadie into staying, facing and
challenging traditional ideas about health and illness.
3.1.5. Compressed Diagnostic Odyssey
Accounts of the diagnostic process highlight that it can feel overwhelming. From the initial home
visit, parents are fast-tracked to a hospital appointment the next day. This sudden shift is apparent in
Sadie’s account:
“[The visitor said] ‘you’ve got an appointment 9 o’clock with the [hospital] team which is centre of excellence,
they’ll be all waiting for you . . . ’, sorry it’s getting a bit emotional [ . . . ] the team were all there explaining and
again I was in denial.”
Sadie depicts a whole new cast of characters suddenly all there waiting for her, perhaps before
she was psychologically ready to engage with the process and their explanations.
Liz’s ‘compressed diagnostic odyssey’ was evident in her vivid recollection of the specific days of
the week when the medical procedures took place. Her memory of “all the different stages” suggested
an indelible memory of undergoing the process, yet she struggled to recall the specific medical
terminology “ . . . then we went to [hospital] so they could do a more—oh what’s the word?—a different type of
sweat test”. These contrasts connote the incongruity of the medical world and her world. Sue describes
her experience similarly:
“The next day we went to the hospital and met the respiratory team, and—It placated us a lot because
they told us that Tilly was CFSPID [ . . . ] what they wanted us to do was come in for lots of tests and take her
for a sweat test, she wanted to start her on a course of erm antibiotics straight away, and all the other erm . . .
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she needed fetal [sic] elastase tests [...] hospital over the next six weeks quite a lot, er found out that she was
pancreatic sufficient so she didn’t need any enzymes, er then we put her in for a sweat test, but it was inconclusive
so she’s had to have another four or five.”
Sue was instantly immersed into a tangibly exhausting series of procedures, the unfamiliarity
of the medical world connoted by her hesitative use of terminology. Sue’s ‘placation’ on learning of
CFSPID reinforces the state of high-distress she had been in, like Harry, for whom the outcome was
that “I didn’t think he’d be dead by age 5 anymore”. Indeed, although all parents described the diagnostic
process as exhausting, they unanimously saw “the hospital day” (Harry) as a turning point, when they
received adequate information and support, “we met the consultant who was then fantastic [ . . . ], and who
explained the whole thing” (Jim).
3.1.6. A Situation that is Incongruent with the Traditional Medical Model
Rather than noticing symptoms and obtaining a diagnosis, parents were suddenly given
information that clashed with their experience of their child “as far as I knew she was fit and healthy”
(Sue), “she’s not in hospital . . . she hasn’t got an open wound” (Sadie). Guy described this:
“It was so out of the blue, it wasn’t like she was an ill child and then somebody comes to the door and
goes, she’s tested positive for this, and you’d know straight away wouldn’t you, [ . . . ] that fix the jigsaw that’s,
that’s what we’re dealing with here, it wasn’t like that, she was healthy—still is.”
Guy’s jigsaw metaphor suggests his experience did not align with his expectations of the diagnostic
process and was discombobulating. Anna explored the emotional impact of this:
“They say ‘Yeah, you’ve got a lovely healthy beautiful baby boy’, and they place him in your arms and
you think phew, [ . . . ] everything’s alright. And then 3 weeks later you’re told it’s actually not, and that’s
really hard.”
Anna felt secure in the belief that she had a healthy child, only for this to be reversed.
Anna experienced the same emotional impact as if Ben had a conclusive disease.
3.1.7. Utility of Labelling
Parents gave a range of interpretations of the power of the CFSPID label. For Sue, ordinary
occurrences were interpreted in the context of disease:
“She has to be careful about where she plays, splashing in muddy puddles and things like that when she goes
to play areas, if there’s someone coughing near her I have to make sure that they’re not coughing on her, cos she
can pick up a cough quite easily. She seems to pick up everything that everybody else has got but, you never
know how much of that is just [ . . . ] child, and how much of it is what, what she’s got.”
Sue’s account suggests a struggle to reconcile a view of Tilly as a typical child with knowledge of
CFSPID. Sue appears to need to hyper-control the environment, suggesting that disease is a constant
threat. Similarly, Molly remained anxious that 4-year-old Ruby’s activities were potentially “dangerous
for your lungs” (Molly). Inherent to these concerns is the continued threat of respiratory illness, conferred
by their perception of the CFSPID label.
Harry discussed how the term ‘CFSPID’ was only introduced to him and Anna recently:
“I never refer to him as SPID, I just say he’s got CF [ . . . ] I throw in sometimes that it’s associated with
a milder form, but when you’re talking to people, on the whole, they don’t know anyway, so [ . . . ]”
When asked about the effect of the new label, neither parent felt it had changed their thinking.
Harry suggests that one use of a diagnostic label is communicating with others about his child. He does
this by reverting to the known diagnosis of ‘a mild form of CF’.
Liz and Guy also discussed the utility of a diagnostic label as a communicative tool, such as for
school, “I don’t put it on forms or anything cos she hasn’t got a condition” (Liz). Unlike other diagnoses,
CFSPID does not allow intervention and treatment, “You’d only put something in if there’s a practical
[ . . . ] but they couldn’t do anything” (Guy)—so they have no place for it in their lives: “The thought
of it being used as a label drives me insane, I couldn’t imagine it” (Guy). Jim also considered this issue,
with a different outcome:
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[ . . . ] whether there was kind of even a consideration as to whether people need to know if their child’s got
CFSPID? Erm, but I would say for us, I would still want to know—cos even though it’s not impacting on our
life we’re still doing things as preventative, to make sure that she’s gonna be as healthy as possible, even though
she’s not symptomatic. So there would never be an occasion where I think, ‘oh I wish I didn’t know’.”
Jim’s hesitance suggests he may have felt uncomfortable raising this, as medicine is traditionally
revered. Jim concluded that knowing about CFSPID is right for his family but acknowledged that others
may feel differently. Interestingly, a healthy child in context of CFSPID becomes “not symptomatic”,
and routine healthy choices become “preventative”.
Like Sue and Jim, Sadie appeared to value the greater control over her child’s health risk:
“I feel she’s a bit more fortunate [ . . . ] gets a first-class MOT every year [ . . . ] anything that’s gonna go
wrong [ . . . ] we’ll be ahead of the game every single time.”
Although presented as a positive aspect of CFSPID, Sadie’s consideration of what may “go wrong”
suggests constant apprehension of illness developing. Her insights hint at a new medical model, or set
of beliefs about how illness is identified and managed, based on monitoring for known risks:
“Is it gonna cause problems is there gonna be issues, yeah, it’s like having fair skin, if you go in the sun too
long you’re gonna get burnt, but if you put a factor on, y’know, you’re gonna prevent it.”
Sadie’s analogy raises questions about predictive medicine. A genetic propensity to sunburn is
not a diagnosis, whereas CFSPID carries additional meaning and effects.
3.2. Making Certainty Out of Uncertainty
3.2.1. Liminality and Uncertainty
All parents were asked to place their child on a continuum of ‘completely healthy’ to ‘serious
health condition’ and explain why. Some appeared to find this challenging, “erm . . . I think she’s probably
just under halfway” (Sue). Anna and Harry also put Ben “right in the middle, cos we don’t know yet, it could
go either way” (Anna), suggesting the inconclusive diagnosis put them in a liminal space:
HARRY: “ . . . and if it wasn’t for that potential you’d put him up there wouldn’t you [‘totally healthy
child’], but yeah probably middle because there is that chance [ . . . ] but we are taking into account the potential
for things to go wrong, if it was just today and you didn’t know he had it you’d put him as completely healthy
wouldn’t you.”
Though Ben appears healthy, the underlying genotype stops Anna and Harry seeing him as
so, with both concluding “It’s the unknown.” Multiple references to uncertainty, “we don’t know yet”,
“potential”, “could”, “chance”, suggest the parents’ apprehension.
Liz and Guy were the only ones to thoroughly reject the diagnosis, “[laughing] no question, I’d put
her here [marks ‘completely healthy’]” (Guy). Guy appeared to find it laughable that this was even being
asked. However, by taking part in the interview, he was perturbed to realise that the picture was not as
certain as he had thought, “I mean [ . . . ] do people mark here? [‘serious condition’]”, “I’m just trying to
figure out [...] how could you say [ . . . ]?”.
Sadie marked Mia ‘completely healthy’, but also conceded “you don’t know what’s round the corner
for these kids, they’re doing fine now but in 5, 6 years they might not be”. The uncertain future was also
discussed by Molly and Jim. Molly quickly marked Ruby ‘completely healthy’, but Jim suggested it
is less binary, “[ . . . ] up towards this end”. Despite her previous certainty, Molly acknowledged the
“chance” of a less positive outcome:
“[The doctor] said, ‘We still don’t know what 30 years, 40 years will look like, on her lungs’, so y’know it’s
still keeping that in in the back of our mind all the time that there is that chance [ . . . ] Especially cos they don’t
know what the future could look like, it’s that uncertainty now, for this type of generation.”
Molly notes that CFSPID’s long-term prognosis is unknown for both parents and professionals,
which again may shake the traditional view of medicine as a certain institution.
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3.2.2. Tension of Idiosyncratic Forms of Certainty
Individuals created their own unique certainties to resolve the uncertainty of CFSPID. Dissonance
arose between parents and children, professionals and parents, and within couples. For Sue, certainty
appeared to be conferred by the prophylactic medical regimen that 3-year-old Tilly has been on
since diagnosis:
“It was gung-ho from the start and we’ve never really minimised anything we’ve never dropped her
medication [...] all this prevention has stopped her getting ill, she could’ve been very poorly, we’ll never know
will we.”
Sue cannot be sure that intervention makes a significant difference, but by embracing diagnosis
she is reassured by the medical world. Medication is seen to prevent illness, but also keeps Sue’s
uncertainty and anxiety at bay. Sue sees the diagnosis as her battle (“gung-ho”), allowing her greater
control over Tilly’s health. This is similar to Jim’s account.
In contrast, Guy, whose daughter Ava is not receiving treatment, rejects the diagnosis:
“It doesn’t achieve anything, she’s not ill so you can’t say she’s got anything [laughs] [ . . . ] There’s no
effect on her life, no effect on our life—we were made aware of it, it was dealt with [ . . . ] No so I don’t, er I dunno
how you could say you’ve got, how people would say their child’s got CF or anything cos they haven’t.”
Guy and Liz appear to attempt to understand the situation by vehemently rejecting diagnosis,
appearing to find it unfathomable that anyone would see CFSPID as such. However, Molly’s story
suggests this line cannot necessarily always be firmly drawn:
[the daughter] used to say she couldn’t tidy up because she’s got cystic fibrosis [ . . . ] she tried to use it as
an excuse, but we’ve told her she’s got no excuse because look, a completely healthy child should do all the tidying
up, shouldn’t they Ruby?”
The power of labels is apparent in this example of a very young child embracing diagnosis.
Molly and Jim reject the idea of Ruby seeing herself as ill, invoking ‘a healthy child’ to help her
understand her identity. However, Ruby’s awareness of ‘having CF’ suggests that, at a young age,
her sense of her situation potentially diverges from her parents’.
Different conceptualisations of CFSPID were not limited to individuals and families. Anna and
Harry discussed the recent introduction of the CFSPID label, highlighting the dissonance between
their views, and the views of healthcare professionals:
ANNA: “Yeah they said ‘oh we’ve got a new term now for Ben now he’s a CFSPID’, I said it sounds like it’s
an insult.”
The account of the doctor casually mentioning this is at odds with the emotional weight of their
interview. The introduction of the new label appears to have undermined the certainty that they had
worked to achieve over the years. Anna’s creation of certainty involved using her understanding of
a traditional medical model to understand and accept the diagnosis:
“We do know that he’s got a faulty gene that does affect, it doesn’t work as well as ours does at getting the
salt and the chloride around the body, we do know that he’s not completely healthy even though he looks it [ . . . ]
it’s a fact.”
Anna appears more deterministic than Harry, who focuses more on the phenotype (“surface level”)
than the genotype. Harry suggested that the impact of the diagnosis, and the discrepancy between
their individual adaptations to CFSPID, has caused damage: “I think it’s had lasting probably detrimental
effects on the marriage [ . . . ] the dynamic has changed”.
Discrepancy was also experienced by Sadie and her ex-husband, with deleterious effects:
“He accused me of Munchausen by proxy” (Sadie). Sadie’s ex-husband is able to reject CFSPID entirely in
a way that would be impossible with a more obvious condition, leading to potential psychological
harm. Again, because CFSPID is unseen and uncertain, Sadie was frustrated by inconsistency
(“moving the goalposts”) from the professionals whom she looked to for guidance with shared custody.
This exacerbated an already difficult situation:
“The physio had to be done, and then it’s like ‘Well if dad doesn’t do the physio, as long as she’s having
a little run round’, and I’m going ‘Which is it?!’”
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4. Discussion
This study furthers our understanding of the psychological impact of CFSPID designation
following NBS for CF. This is a distinct situation in that parents’ expectations of health outcomes
are being subverted by health care professionals. Although the NBS-positive children can often be
asymptomatic, they have a definite condition. CFSPID moves this one step further by returning
“information” which itself is unclear. Our results suggest that our participants’ experience of learning
about their CFSPID, the uncertainty and, for some, ongoing health concerns had a significant negative
psychological impact, in keeping with the only other qualitative study in this field [12]. For all
parents, initial result communication caused heightened health risk and distress. Parents struggled
to understand CFSPID, as it was incongruent with their preconceived illness and health care beliefs.
There was tension between individuals’ distinct strategies to understand and process the CFSPID
designation and manage uncertainty. Result communication should be changed to ensure that this
does not happen.
We found that screening result communication was a key source of distress. This is a recognised
problem in NBS [17] as delivering results to families is an unavoidable challenge for HCPs.
The experiences of the parents in this study were similar to parents studied by Tluczek et al. [12,18]
who experienced distress in the wait for further testing following positive NBS results. Though
relatively shorter in our study, all parents still found this wait distressing. This echoes the work
by Ulph et al. [6] who suggested that when parents’ information needs are not promptly met it can
trigger anxiety and catastrophizing rumination. Appropriate management of this wait, bearing in
mind the need to not offer false hope to families of infants with ‘proper’ CF, is key. Ensuring parents
receive adequate, prompt, and accurate information, delivered with empathy, may minimise distress.
HCPs should be supported with adequate resources to deliver this. This work fits with other studies
in suggesting that telling parents not to go to the internet is unrealistic [6,12]. Indeed, it may fail to
realise the psychological state triggered in parents on first awareness of a health risk and the need to
take some form of “information gathering action” to lessen this undesirable state. Rather, it would
appear that signposting parents to appropriate sites would be more realistic and beneficial for their
psychological states.
Our findings fit with those of Tluczek et al. [12] in suggesting that anxiety triggered by the
CFSPID result endures for parents. As such, they differ from parents who receive carrier results where
anxiety dissipates after professional information [6]. This may be because there is extant information,
whereas for CFSPID, parents could not be offered an adequately firm explanation of their child’s result,
leaving them in limbo [8]. This may explain some parents’ continued belief that their child had CF,
despite knowing about CFSPID and reporting satisfaction with the information and support received.
A quantitative study may only have noted this latter point, whereas our study suggests the overall
response is more complex.
La Pean and Farrell [19] suggested that initially misleading information following screening
can leave a lasting impression, due to the primacy effect. In our study, parents’ perception of the
initial message they received was that their child had CF. From our results it seems that the initial
communication has a deep and profound impact on the parent’s subsequent beliefs with respect to
their infant’s health risks. Schema theory [20], which posits that knowledge is arranged in groupings
(schema) and that people try to fit new information into these schemas, may be relevant here. For some
parents in our study, this led to anxiety over the potentially benign. This was reinforced by ongoing
monitoring and, in some cases, prophylactic treatment (counter to European Cystic Fibrosis Society
guidance [21]), echoing concerns that such approaches may over-medicalise and confer ‘the sick
role’ [11,22]. Appropriate information at the outset and reassurance that their child is not at immediate
risk and does not have CF is critical in moderating these parents’ responses to CFSPID. It is particularly
important to stress that their child does not necessarily have classic CF, since parents will often be
cared for in CF clinics and signposted to CF resources, as such it may not be an easy message for
parents to assimilate. It is worth noting that UK guidance has recently changed such that a preparatory
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phone call to parents is recommended prior to NBS result delivery [21]. This may help to reduce the
anxiety-provoking aspect of HCPs ‘turning up unannounced’, as described by the parents in this study.
Though research which has captured pre-meeting phone call practice suggests there is still a high level
of distress and that better preparing parents before NBS would be beneficial [6].
Results suggest that CFSPID subverts accepted ideas of health and illness, in giving parents
a medical result which does not match their child’s observed phenotype. The results also suggest that
parents may cope with this disparity by forming a strong belief in either the ‘healthy’ genotype or
the ‘ill’ phenotype. Parents are generally unaware of the purpose or potential outcomes of NBS [17],
less so the possibility of results of uncertain significance [2]. Appropriate explanation of this possibility,
balancing pragmatism with reassurance that not all results are necessarily threatening, may help
parents adapt to this new form of screening.
All parents were aware that CFSPID was a new classification. The designation was introduced in
2016 after a complex decision process by international stakeholders [8]. This process is not usually
witnessed by laypeople, the names of diseases strongly influence our understanding of them and do
not usually change. This may explain why most parents appeared to stick to the most salient aspect
of the label, ‘CF’. In light of the possible effect of schemas [20], our results suggest that the names of
inconclusive diagnoses must not misleadingly invoke diagnosis threat. Indeed, the importance of the
label echoes findings by Tluczek [12] and the concerns of professionals in the original designation
process [8], reflects the complexity of this issue.
We found that CFSPID causes uncertainty, corroborating extant concerns [8]. Results suggest that
individuals, including HCPs as well as family, develop idiosyncratic mechanisms to attempt to form
certainty. This is consistent with work by Dillon and Carson [23], who found that parents of children
having further testing after a positive CF screen managed uncertainty in a range of ways. The range of
mechanisms suggested by our results may be loosely mapped onto the options proposed by Massie
& Gillam [11], parents ranged from managing their child as if they had CF to rejecting the diagnosis
and thinking of them as a healthy carrier. Our results showed that parents in the same geographical
location, with children with the same designation, vary widely in their treatment and perception
of their children as ‘ill’ or ‘healthy’. Results suggest that many factors are involved here, including
individual differences in health beliefs, parents’ relationships and support networks, and the children
themselves, in addition to how the initial screening result and diagnostic assessment is experienced.
All of these factors should be appreciated by the HCPs looking after the family.
Our results showed how tensions may arise between the views of parents and HCPs. Parents
need support to manage the uncertainty of CFSPID, so that relationship damage is minimised. HCPs
may be instrumental in managing uncertainty, through consistency and accuracy in the initial stages
of diagnosis [23]. All of our parents reported positive experiences with HCPs, but there were some
tensions between doctors’ and parents’ understanding of the CFSPID label, again emphasising the
important role that illness labels play in adaptation. There is awareness that this is an uncertain
situation not just for parents but for HCPs too [8], which is another aspect of CFSPID subverting the
traditional medical model.
5. Strengths & Limitations
The interview schedule was designed with a clinician with considerable experience of working
with parents with CFSPID and debates around management and a researcher with expertise in
qualitative methods and research regarding NBS impact and communication. Drawing tasks, used to
elicit responses conceptually, appeared to help parents reflect on how they viewed their child and
their experience. In concordance with IPA methodology [16], the interviewer was trained to use the
interview schedule and other materials flexibly and sensitively, and the conversations were driven
by the participants. In fitting with IPA quality guidance [24], we have been transparent in order to
enable readers to understand our process by providing a copy of the interview schedule, contextual
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information, and extensive process information. We have also focused on a defined in-depth topic and
the data examples illustrate the depth and quality of data gained.
Meeting criteria set by Guba and Lincoln [25] specifically defined by Smith for IPA, we have
illustrated rigour by giving the reader a sense of how themes are represented across the dataset as
well as showing how experiences are idiosyncratic and differ, and yet also where they converge to
illustrate a universal truth. We have allowed space and depth to explain each theme and subtheme
and when presenting data, we have been careful to ensure that it is interpreted, illustrating the double
hermeneutic, rather than positioned as a statement of fact.
The sample is in keeping with the guidance on IPA studies, where in the interest of ensuring
depth-of-analysis, researchers are advised against large sample sizes. The analysis was supervised
by an experienced qualitative researcher. Within the practical constraints of study recruitment and
duration, the research has successfully gleaned insight into parents’ experiences with considerable
variation in parental interpretation and contextual situations. The lack of fathers’ perspectives
has been raised as a concern in newborn screening studies [1], yet a strength of this study is that
a significant proportion were fathers. Furthermore, couples were interviewed together which enabled
an appreciation of the considerable variance in the interpretation and impact of CFSPID and the tension
this could cause in couples.
All research is affected by the bias of those who are willing to participate and give time to provide
their accounts. Families were from the same geographical area of England and under the same health
service, which may limit our understanding of CFSPID diagnoses in other areas. Families were majority
white and relatively aﬄuent and educated to a level that enabled them to engage in discussion of
difficult issues, a feature similar to other studies concerning CF screening in particular [7,26]. Although
this is commonly taken as a weakness in study evaluation, the fact that our participants struggled
to comprehend and assimilate their experiences strengthens the need for communication guidance
to ensure the wide range of parents who experience newborn screening are adequately informed
and supported. Further qualitative research targeting more diverse groups would be beneficial in
developing this.
6. Conclusions
The results from this detailed study illustrate the negative psychological impact of a CFSPID
designation on parents. Factors leading to this may be unavoidable, but it is clear that with some
straightforward changes in approach, the degree of impact could be lessened. A priority for change
should be the first interaction with the family where the NBS result is presented accurately and
empathetically, with a clear appreciation of what is to come. Subsequently, good communication is
key and hopefully now that the CFSPID designation and management are established, CF HCPs will
provide a more consistent message and advice to families.
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